*ST Changyao Accumulated Litigation Amount Exceeds 51.45 Million Yuan Over Twelve Consecutive Months, Accounting for 11.89% of Absolute Net Assets Value

Changjiang Pharmaceutical Holdings Co., Ltd. (Stock abbreviation: *ST Changyao (Rights Protection), Stock code: 300391) announced on March 18, 2026, that the company and its subsidiaries have been involved in a total of 12 months of litigation and arbitration cases, with a total claimed amount of approximately 51.45 million yuan, accounting for 11.89% of the most recent audited net assets. Among these, the company received a legal document on March 17 regarding a new financial loan contract dispute, with a claimed amount of 36.99 million yuan.

The announcement shows that the total amount involved in the above cases has exceeded 10 million yuan and accounts for more than 10% of the company’s most recent audited net assets, which requires timely disclosure according to the relevant regulations of the Shenzhen Stock Exchange Listing Rules. The company emphasizes that the litigation and arbitration cases announced this time are not expected to impact the company’s current or future profits.

As of the date of this announcement, aside from the disclosed matters, the company and its subsidiaries have no other litigation or arbitration cases that need to be disclosed but have not been disclosed. The company will continue to disclose updates on the cases in accordance with the phased disclosure principle.

Below is a summary of the main litigation and arbitration cases involving *ST Changyao and its subsidiaries over the past 12 months:

In these cases, *ST Changyao is mainly sued as a guarantor or joint liable party. The largest amount involved is in the financial loan contract dispute, where the plaintiff, Bank of China Co., Ltd. Guyuan Branch, demands Ningxia Changyao Liangsheng Pharmaceutical Co., Ltd. repay the principal of 34.9 million yuan plus interest and penalties, and requires *ST Changyao and others to bear joint repayment responsibility. The plaintiff also claims a priority right to seize 717 sets of machinery and equipment registered under Ningxia Changyao Liangsheng Pharmaceutical Co., Ltd.

Click to view the original announcement>>

Disclaimer: The market carries risks; investment should be cautious. This article is automatically published by an AI model based on third-party databases and does not represent Sina Finance’s views. All information in this article is for reference only and does not constitute personal investment advice. Please refer to the actual announcement for accuracy. If you have any questions, contact biz@staff.sina.com.cn.